Comparison of the immunogenicity and tolerability of influenza A virus vaccine H1N1 [2009 A/H1N1 MF59-adjuvanted influenza vaccine] and influenza virus vaccine [seasonal 2009-10 virosomal-adjuvanted influenza vaccine], administered simultaneously and 1 month apart, in control subjects and paediatric kidney transplant patients.

Trial Profile

Comparison of the immunogenicity and tolerability of influenza A virus vaccine H1N1 [2009 A/H1N1 MF59-adjuvanted influenza vaccine] and influenza virus vaccine [seasonal 2009-10 virosomal-adjuvanted influenza vaccine], administered simultaneously and 1 month apart, in control subjects and paediatric kidney transplant patients.

Completed
Phase of Trial: Phase II

Latest Information Update: 17 Feb 2011

At a glance

  • Drugs Influenza A virus vaccine-H1N1 (Primary) ; Influenza virus vaccine (Primary) ; MF 59
  • Indications Influenza A virus H1N1 subtype; Influenza A virus H3N2 subtype
  • Focus Pharmacodynamics
  • Most Recent Events

    • 17 Feb 2011 New trial record
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top